^
Association details:
| Biomarker: | SLC8A1-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report
Published date:
08/11/2022
Excerpt:
...we reported a patient with advanced lung adenocarcinoma harboring a SLC8A1-ALK fusion who benefited from first-line treatment with alectinib. After 2 months of taking alectinib, the targeted lung lesions and intrahepatic metastases regressed significantly.
DOI:
https://doi.org/10.1515/biol-2022-0090
